|
1
|
Su Z, Zang T, Liu ML, Wang LL, Niu W and
Zhang CL: Reprogramming the fate of human glioma cells to impede
brain tumor development. Cell Death Dis. 5:e14632014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martinez R, Rohde V and Schackert G:
Different molecular patterns in glioblastoma multiforme subtypes
upon recurrence. J Neurooncol. 96:321–329. 2010. View Article : Google Scholar :
|
|
5
|
Bastien JI, McNeill KA and Fine HA:
Molecular characterizations of glioblastoma, targeted therapy, and
clinical results to date. Cancer. 121:502–516. 2015. View Article : Google Scholar
|
|
6
|
Karsy M, Gelbman M, Shah P, Balumbu O, Moy
F and Arslan E: Established and emerging variants of glioblastoma
multiforme: Review of morphological and molecular features. Folia
Neuropathol. 50:301–321. 2012. View Article : Google Scholar
|
|
7
|
Cuddapah VA, Robel S, Watkins S and
Sontheimer H: A neurocentric perspective on glioma invasion. Nat
Rev Neurosci. 15:455–465. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carlsson SK, Brothers SP and Wahlestedt C:
Emerging treatment strategies for glioblastoma multiforme. EMBO Mol
Med. 6:1359–1370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fialho AM, Salunkhe P, Manna S, Mahali S
and Chakrabarty AM: Glioblastoma multiforme: Novel therapeutic
approaches. ISRN Neurol. 2012:6423452012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim K, Fisher MJ, Xu SQ and el-Deiry WS:
Molecular determinants of response to TRAIL in killing of normal
and cancer cells. Clin Cancer Res. 6:335–346. 2000.PubMed/NCBI
|
|
11
|
Suliman A, Lam A, Datta R and Srivastava
RK: Intracellular mechanisms of TRAIL: apoptosis through
mitochondrial-dependent and -independent pathways. Oncogene.
20:2122–2133. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stuckey DW and Shah K: TRAIL on trial:
Preclinical advances in cancer therapy. Trends Mol Med. 19:685–694.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bagci-Onder T, Agarwal A, Flusberg D,
Wanningen S, Sorger P and Shah K: Real-time imaging of the dynamics
of death receptors and therapeutics that overcome TRAIL resistance
in tumors. Oncogene. 32:2818–2827. 2013. View Article : Google Scholar :
|
|
14
|
Deng Y, Lin Y and Wu X: TRAIL-induced
apoptosis requires Bax-dependent mitochondrial release of
Smac/DIABLO. Genes Dev. 16:33–45. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kauer TM, Figueiredo JL, Hingtgen S and
Shah K: Encapsulated therapeutic stem cells implanted in the tumor
resection cavity induce cell death in gliomas. Nat Neurosci.
15:197–204. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bagci-Onder T, Wakimoto H, Anderegg M,
Cameron C and Shah K: A dual PI3K/mTOR inhibitor, PI-103,
cooperates with stem cell-delivered TRAIL in experimental glioma
models. Cancer Res. 71:154–163. 2011. View Article : Google Scholar
|
|
17
|
Zhang L and Fang B: Mechanisms of
resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther.
12:228–237. 2005. View Article : Google Scholar
|
|
18
|
Du W, Uslar L, Sevala S and Shah K:
Targeting c-Met receptor overcomes TRAIL-resistance in brain
tumors. PLoS One. 9:e954902014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Finlay D, Richardson RD, Landberg LK,
Howes AL and Vuori K: Novel HTS strategy identifies
TRAIL-sensitizing compounds acting specifically through the
caspase-8 apoptotic axis. PLoS One. 5:e133752010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou X, Qiu J, Wang Z, Huang N, Li X, Li
Q, Zhang Y, Zhao C, Luo C, Zhang N, et al: In vitro and in vivo
anti-tumor activities of anti-EGFR single-chain variable fragment
fused with recombinant gelonin toxin. J Cancer Res Clin Oncol.
138:1081–1090. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Horita H, Thorburn J, Frankel AE and
Thorburn A: EGFR-targeted diphtheria toxin stimulates TRAIL killing
of glioblastoma cells by depleting anti-apoptotic proteins. J
Neurooncol. 95:175–184. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stuckey DW, Hingtgen SD, Karakas N, Rich
BE and Shah K: Engineering toxin-resistant therapeutic stem cells
to treat brain tumors. Stem Cells. 33:589–600. 2015. View Article : Google Scholar :
|
|
23
|
Thaci B, Brown CE, Binello E, Werbaneth K,
Sampath P and Sengupta S: Significance of interleukin-13 receptor
alpha 2-targeted glioblastoma therapy. Neuro Oncol. 16:1304–1312.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Heimberger AB, Suki D, Yang D, Shi W and
Aldape K: The natural history of EGFR and EGFRvIII in glioblastoma
patients. J Transl Med. 3:382005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Terabe M, Park JM and Berzofsky JA: Role
of IL-13 in regulation of anti-tumor immunity and tumor growth.
Cancer Immunol Immunother. 53:79–85. 2004. View Article : Google Scholar
|
|
26
|
Maletinska L, Blakely EA, Bjornstad KA,
Deen DF, Knoff LJ and Forte TM: Human glioblastoma cell lines:
Levels of low-density lipoprotein receptor and low-density
lipoprotein receptor-related protein. Cancer Res. 60:2300–2303.
2000.PubMed/NCBI
|
|
27
|
Wolf P and Elsasser-Beile U: Pseudomonas
exotoxin A: From virulence factor to anti-cancer agent. Int J Med
Microbiol. 299:161–176. 2009. View Article : Google Scholar
|
|
28
|
Weldon JE and Pastan I: A guide to taming
a toxin-recombinant immunotoxins constructed from Pseudomonas
exotoxin A for the treatment of cancer. FEBS J. 278:4683–4700.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kunwar S, Chang S, Westphal M, Vogelbaum
M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M,
et al: Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel
wafers for recurrent glioblastoma. Neuro Oncol. 12:871–881. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Auffinger B, Thaci B, Nigam P, Rincon E,
Cheng Y and Lesniak MS: New therapeutic approaches for malignant
glioma: In search of the Rosetta stone. F1000 Med Rep. 4:182012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
van de Water JA, Bagci-Onder T, Agarwal
AS, Wakimoto H, Roovers RC, Zhu Y, Kasmieh R, Bhere D, Van Bergen
en Henegouwen PM and Shah K: Therapeutic stem cells expressing
variants of EGFR-specific nanobodies have antitumor effects. Proc
Natl Acad Sci USA. 109:16642–16647. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shah K, Hingtgen S, Kasmieh R, Figueiredo
JL, Garcia-Garcia E, Martinez-Serrano A, Breakefield X and
Weissleder R: Bimodal viral vectors and in vivo imaging reveal the
fate of human neural stem cells in experimental glioma model. J
Neurosci. 28:4406–4413. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shah K, Tang Y, Breakefield X and
Weissleder R: Real-time imaging of TRAIL-induced apoptosis of
glioma tumors in vivo. Oncogene. 22:6865–6872. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wakimoto H, Kesari S, Farrell CJ, Curry WT
Jr, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu
TC, et al: Human glioblastoma-derived cancer stem cells:
Establishment of invasive glioma models and treatment with
oncolytic herpes simplex virus vectors. Cancer Res. 69:3472–3481.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gimple RC, Bhargava S, Dixit D and Rich
JN: Glioblastoma stem cells: Lessons from the tumor hierarchy in a
lethal cancer. Genes Dev. 33:591–609. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu G, Yuan X, Zeng Z, Tunici P, Ng H,
Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene
expression and chemoresistance of CD133+ cancer stem cells in
glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Reinshagen C, Bhere D, Choi SH, Hutten S,
Nesterenko I, Wakimoto H, Le Roux E, Rizvi A, Du W, Minicucci C and
Shah K: CRISPR-enhanced engineering of therapy-sensitive cancer
cells for self-targeting of primary and metastatic tumors. Sci
Trans Med. 10:eaao32402018. View Article : Google Scholar
|
|
40
|
Dilshara MG, Jayasooriya RGPT, Molagoda
IMN, Jeong JW, Lee S, Park SR, Kim GY and Choi YH: Silibinin
sensitizes TRAIL-mediated apoptosis by upregulating DR5 through
ROS-induced endoplasmic reticulum stress-Ca(2+)-CaMKII-Sp1 pathway.
Oncotarget. 9:10324–10342. 2018. View Article : Google Scholar : PubMed/NCBI
|
